- •
The prevalence of overt mastocytosis has been estimated to be about 10 cases per 100,000 inhabitants. That of monoclonal mast cell activation syndrome and of idiopathic mast cell activation syndrome remains unknown.
- •
Adult patients with mastocytosis predominantly exhibit indolent systemic mastocytosis (ISM) and in children cutaneous mastocytosis (CM) is assumed.
- •
Regression of mastocytosis in children is common and chronic persistence of skin mastocytosis in adults is typical.
- •
Evolution of ISM into
Epidemiology, Prognosis, and Risk Factors in Mastocytosis
Section snippets
Key points
Prevalence of Mastocytosis
Mastocytosis is considered to be an orphan disease (affecting <200,000 people in the United States). There are no epidemiologic studies to define the precise incidence, point prevalence, or cumulative prevalence of mastocytosis in the general population (Box 1). Because of its rarity many doctors were unfamiliar with this disease and did not recognize it. Thus, until recently, the number of recognized patients per single center was not sufficient and not reliable to estimate incidence and
Prevalence of Systemic Disease in Patients with Mastocytosis
The prevalence of systemic disease in patients with mastocytosis depends greatly on the definition of SM, which has been changed in 2001, on the associated development of more sensitive methods for detecting mast cells and clonality (eg, use of the tryptase stain to highlight mast cells), and on the experience of physicians. The extracutaneous tissue that shows the highest numbers of mast cell in systemic involvement and that is still easily available is the bone marrow.20 Whereas in older
Prognosis for Resolution of CM in Children
Data on the natural history of childhood-onset mastocytosis come mostly from studies where the analysis depended on retrospective chart reviews and reporting on skin examinations.26 Although it often has been stated that resolution of the disease would happen in more than 50% of patients, there are only a small number of studies on which this conclusion was based. A recent study attempted to analyze patients with a longer duration of follow-up and re-examined 15 individuals who had been
Risk Factors for More Severe Clinical Disease
In a prospective study of 48 adults and 19 children with MPCM the extent and density of cutaneous lesions were compared with symptomatology, tryptase levels, and bone marrow pathology.32 In children, possibly because of a low number of included patients, symptoms, and available bone marrow pathologies, the extent of cutaneous disease was not associated with systemic involvement or symptomatology. There was a borderline correlation between the extent of cutaneous disease and serum tryptase
References (67)
- et al.
Mastocytosis
Lancet
(1997) - et al.
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Leuk Res
(2001) - et al.
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels
J Allergy Clin Immunol
(2009) - et al.
Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis
Blood
(2007) - et al.
Bone marrow findings in adult patients with urticaria pigmentosa
J Am Acad Dermatol
(1988) - et al.
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
J Allergy Clin Immunol
(2009) - et al.
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)
Blood
(2010) - et al.
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Blood
(2009) - et al.
Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology
J Am Acad Dermatol
(2003) Urticaria pigmentosa
Immunol Allergy Clin North Am
(2004)
Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study
Mayo Clin Proc
Comprehensive mutational profiling in advanced systemic mastocytosis
Blood
Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis
Mod Pathol
Diagnostic value of tryptase in anaphylaxis and mastocytosis
Immunol Allergy Clin North Am
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
J Allergy Clin Immunol
Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
Blood
IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis
Clin Immunol
Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings
Lancet
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase. A study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
J Allergy Clin Immunol
Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis
J Allergy Clin Immunol
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis
Bone
Classification and diagnosis of mastocytosis: current status
J Invest Dermatol
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria
Eur J Clin Invest
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
Wien Klin Wochenschr
Prevalence of indolent systemic mastocytosis in a Dutch region
J Allergy Clin Immunol
Mastocytosis
Chem Immunol Allergy
Pediatric mastocytosis
J Invest Dermatol
C-kit activating mutation in a neonate with in-utero presentation of systemic mastocytosis associated with myeloproliferative disorder
Br J Haematol
Mastocytosis
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis
Haematologica
Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome
Int Arch Allergy Immunol
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal
Int Arch Allergy Immunol
Cited by (143)
Metformin: A potential adjunct for treatment of systemic mastocytosis
2024, Journal of Allergy and Clinical Immunology: GlobalVertebral fracture in a 7-year-old boy with indolent systemic mastocytosis
2023, Journal of Allergy and Clinical Immunology: In PracticeAn Atypical Case of Hymenoptera Venom Anaphylaxis
2023, Journal of Allergy and Clinical Immunology: In PracticeMast cell distribution and prevalence in the murine urinary bladder
2024, BMC UrologySafety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis
2024, Acta Medica Portuguesa
The author has nothing to disclose.